TrialOpen forum infectious diseases2024

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study.

Mounir Ait-Khaled et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.